Inogen, Inc.
INGNHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Inogen, Inc. (INGN) is listed under Medical Devices. Valued at $143.8M, INGN is a micro-cap name in its sector. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Market Cap
$143.8M
Beta
1.58
P/E (TTM)
—
P/E (Fwd)
-33.88
EPS (TTM)
$-0.91
EPS (Fwd)
$-0.16
ROE
-13.1%
ROA
-5.8%
Cash
$105.5M
Total Debt
$15.8M
Free CF
-$1.8M
52W Change
-36.5%
Annual Financials
Cash vs Debt
Where INGN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, INGN finished 14.58% below its 150-day moving average ($6.31) and 15.91% below its 200-day moving average ($6.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INGN overbought or oversold?
At the September 3, 2026 close, INGN's RSI(14) was 25.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $105.5M in cash and $15.8M in debt, INGN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$1.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -13.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $377.2M (2022) to $348.7M (2025).
Inogen, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Inogen, Inc. and its sector.